Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Alexion Pharmaceuticals	Shiseido	Astellas Pharma	BeiGene	Takeda Pharmaceutical
Symbol	NASDAQ:ALXN	OTCMKTS:SSDOY	OTCMKTS:ALPMY	NASDAQ:BGNE	OTCMKTS:TKPYY
Price Information
Current Price	$155.01	$68.32	$14.92	$308.27	$17.25
52 Week Range	Hold	Hold	Buy	Hold	N/A
MarketRank™
Overall Score	1.7	0.9	1.7	1.3	1.0
Analysis Score	1.2	0.0	0.0	2.2	0.0
Community Score	3.1	2.2	2.7	2.8	2.7
Dividend Score	0.0	1.7	2.5	0.0	0.8
Ownership Score	1.7	0.0	0.0	0.8	0.0
Earnings & Valuation Score	2.5	0.6	3.1	0.6	1.3
Analyst Ratings
Consensus Recommendation	Hold	Hold	Buy	Hold	N/A
Consensus Price Target	$153.86	N/A	N/A	$319.38	N/A
% Upside from Price Target	-0.74% downside	N/A	N/A	3.60% upside	N/A
Trade Information
Market Cap	$34.08 billion	$27.29 billion	$27.78 billion	$28.23 billion	$26.95 billion
Beta	1.33	0.33	0.63	0.91	0.42
Average Volume	2,663,334	19,610	75,832	314,904	979,605
Sales & Book Value
Annual Revenue	$4.99 billion	$10.38 billion	$11.97 billion	$428.21 million	$15.99 billion
Price / Sales	6.83	2.63	2.32	65.92	1.69
Cashflow	$11.58 per share	$3.28 per share	$1.20 per share	N/A	$2.29 per share
Price / Cash	13.39	20.85	12.47	N/A	7.52
Book Value	$50.91 per share	$11.93 per share	$6.28 per share	$15.87 per share	$11.62 per share
Price / Book	3.04	5.73	2.38	19.42	1.48
Profitability
Net Income	$2.40 billion	$676.77 million	$1.80 billion	$-948,630,000.00	$1.68 billion
EPS	$9.74	$1.72	$0.96	($15.80)	N/A
Trailing P/E Ratio	36.22	N/A	21.62	N/A	12.11
Forward P/E Ratio	13.21	73.46	9.82	N/A	∞
P/E Growth	0.75	N/A	N/A	N/A	N/A
Net Margins	16.32%	-1.33%	11.03%	-569.22%	7.84%
Return on Equity (ROE)	23.16%	0.95%	13.24%	-56.81%	11.35%
Return on Assets (ROA)	14.76%	0.40%	7.89%	-39.93%	5.57%
Dividend
Annual Payout	N/A	$0.27	$0.29	N/A	$0.58
Dividend Yield	N/A	0.40%	1.94%	N/A	3.36%
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	15.70%	30.21%	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.22%	0.25%	N/A	0.04%	0.48%
Current Ratio	3.81%	1.11%	1.23%	7.69%	1.42%
Quick Ratio	3.26%	0.68%	0.99%	7.64%	1.12%
Ownership Information
Institutional Ownership Percentage	87.27%	0.14%	0.18%	60.65%	0.19%
Insider Ownership Percentage	4.03%	N/A	N/A	9.00%	N/A
Miscellaneous
Employees	3,837	40,000	15,883	5,300	N/A
Shares Outstanding	219.85 million	399.39 million	1.86 billion	91.57 million	1.56 billion
Next Earnings Date	5/5/2021 (Estimated)	5/11/2021 (Estimated)	5/13/2021 (Estimated)	5/10/2021 (Estimated)	N/A
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Takeda Pharmaceutical (OTCMKTS:TKPYY) Shares Down 0.3% americanbankingnews.com - March 27 at 12:26 AM
	Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease feeds.benzinga.com - February 10 at 6:47 AM
	Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)] benzinga.com - December 16 at 9:42 AM
	Takeda preparing to sell Japan consumer health unit to Blackstone -Kyodo financialpost.com - August 18 at 10:51 PM
	Takeda Pharmaceutical Company Limited -- Moody's adds details on Takeda's rated senior unsecured notes finance.yahoo.com - June 30 at 7:12 AM
	Why Translate Bio's Stock Is Trading Lower Today feeds.benzinga.com - June 25 at 11:21 AM
	Takeda Issues Update From AHEAD Study With ADVATE In Hemophilia A Patients www.nasdaq.com - June 15 at 8:33 AM
	Takeda says coronavirus treatment trial using recovered patients’ blood could start in July business.financialpost.com - May 13 at 8:19 PM
	Takeda says coronavirus treatment trial using recovered patients' blood could start in July feeds.reuters.com - May 13 at 8:02 PM
	Japan’s Takeda sells $670 mln of Europe OTC assets to pare debt business.financialpost.com - April 24 at 5:01 AM
	Japan’s Takeda plans to sell consumer health unit for around $3.7 bln – Nikkei business.financialpost.com - April 24 at 12:38 AM
	Takeda Pharma TOURMALINE-MM2 Phase 3 Study Meets Primary Endpoint markets.businessinsider.com - March 10 at 8:57 AM
	Japan's Takeda forecasts surprise full-year operating profit feeds.reuters.com - February 4 at 6:56 AM
	Nidda Healthcare Holding GMBH -- Moody's affirms Nidda's B3 CFR following M&A transactions; stable outlook finance.yahoo.com - November 11 at 5:07 PM
	Takeda To Sell Select Products To STADA For $660 Mln; Stock Up www.nasdaq.com - November 5 at 7:07 AM
	Takeda scraps late-stage amyloidosis study feeds.reuters.com - June 5 at 5:53 PM
	Takeda FY18 Profit Down, Revenues Climb markets.businessinsider.com - May 14 at 11:35 AM
	Takeda To Sell Dry Eye Drug, Surgical Patch To Novartis, J&J For Up To $5.7 Bln markets.businessinsider.com - May 9 at 11:09 AM
	Takeda sells dry eye drug to Novartis to help cut debt feeds.reuters.com - May 8 at 11:13 PM
	Shire Acq Inv Ireland Designated Activity Co -- Moody's announces completion of a periodic review of ratings of Shire Acq Inv Ireland Designated Activity Co finance.yahoo.com - February 15 at 4:18 PM
	Takeda Reportedly Considers Sale Of $3 Billion In Emerging-Market Assets www.nasdaq.com - January 22 at 10:44 AM
	This pharmaceutical company is like four biotechs in one,... finance.yahoo.com - January 15 at 4:18 PM
	Takeda Pharmaceutical CEO Talks Big Pharma Trends finance.yahoo.com - January 15 at 4:18 PM
	Japan Olympics boss suspected of campaign bribery news.yahoo.com - January 11 at 4:08 PM
	Olympics-IOC opens ethics file on Takeda, to meet Friday finance.yahoo.com - January 11 at 11:04 AM

Date	Company	Brokerage	Action
3/29/2021	Alexion Pharmaceuticals	SVB Leerink	Reiterated Rating
2/4/2021	Alexion Pharmaceuticals	Piper Sandler	Downgrade
1/8/2021	Alexion Pharmaceuticals	Raymond James	Downgrade
12/16/2020	Alexion Pharmaceuticals	Truist	Downgrade
12/15/2020	Alexion Pharmaceuticals	Smith Barney Citigroup	Downgrade
12/15/2020	Alexion Pharmaceuticals	Roth Capital	Boost Price Target
12/15/2020	Alexion Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Reiterated Rating
12/14/2020	Alexion Pharmaceuticals	Robert W. Baird	Downgrade
12/14/2020	Alexion Pharmaceuticals	Wedbush	Downgrade
12/14/2020	Alexion Pharmaceuticals	Royal Bank of Canada	Boost Price Target
12/14/2020	Alexion Pharmaceuticals	BMO Capital Markets	Downgrade
12/14/2020	Alexion Pharmaceuticals	Credit Suisse Group	Downgrade
11/19/2020	Alexion Pharmaceuticals	Sanford C. Bernstein	Initiated Coverage
10/30/2020	Alexion Pharmaceuticals	Svb Leerink	Lower Price Target
10/30/2020	Alexion Pharmaceuticals	Morgan Stanley	Lower Price Target
10/28/2020	Alexion Pharmaceuticals	UBS Group	Initiated Coverage
11/11/2020	Shiseido	Daiwa Capital Markets	Upgrade
9/30/2020	Shiseido	Jefferies Financial Group	Upgrade
9/4/2020	Shiseido	The Goldman Sachs Group	Downgrade
8/7/2020	Shiseido	CLSA	Downgrade
6/24/2020	Shiseido	JPMorgan Chase & Co.	Upgrade
9/13/2018	Astellas Pharma	Deutsche Bank Aktiengesellschaft	Downgrade
3/16/2021	BeiGene	HSBC	Boost Price Target
3/8/2021	BeiGene	China Renaissance Securities	Initiated Coverage
2/25/2021	BeiGene	Cowen	Boost Price Target
12/8/2020	BeiGene	LADENBURG THALM/SH SH	Upgrade
11/6/2020	BeiGene	Maxim Group	Downgrade
3/13/2020	BeiGene	Macquarie	Upgrade

(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources